Ventures Fund Iv, L.P.Flags... Net Worth

Insiders trading at Editas Medicine Inc

Over the last 9 years, insiders at Editas Medicine Inc have traded over $73,429,036 worth of Editas Medicine Inc stock and bought 241,700 units worth $4,697,822 . The most active insiders traders include Andrew A. F. Hack, Kevin P Starr, and Kevin Bitterman. On average, Editas Medicine Inc executives and independent directors trade stock every 22 days with the average trade being worth of $126,770. The most recent stock trade was executed by Baisong Mei on 4 September 2024, trading 518 units of EDIT stock currently worth $1,772.

What does Editas Medicine Inc do?

unlocking the promise of genome editing to deliver life-changing medicines. editas medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.

Editas Medicine Inc executives and stock owners

Editas Medicine Inc executives and other stock owners filed with the SEC include:

• Cynthia Collins,
  President, Chief Executive Officer, Director
• Charles Albright,
  Executive Vice President, Chief Scientific Officer
• Dr. Bruce E. Eaton Ph.D.,
  Exec. VP & Chief Bus. Officer
• Michelle Robertson,
  CFO, Principal Accounting Officer, Treasurer & Assistant Sec.
• David Scadden,
  Independent Director
• James Mullen,
  Independent Chairman of the Board
• Jessica Hopfield,
  Independent Director
• Andrew Hirsch,
  Independent Director
• Dr. Lisa A. Michaels M.D.,
  Exec. VP & Chief Medical Officer
• Akshay Vaishnaw,
  Independent Director
• James C. Mullen,
  Chairman, Pres & CEO
• Lisa Michaels,
  Executive Vice President, Chief Medical Officer
• Mark Mullikin,
  Investor Relations Officer
• Gad Berdugo,
  Chief Business Officer
• Harry Gill,
  Senior Vice President - Operations
• Michelle Robertson,
  Chief Financial Officer
• Dr. Gilmore O'Neill,
  Pres & CEO
• Charlene Stern J.D., Ph.D.,
  Exec. VP & Gen. Counsel
• Ron Moldaver,
  Investor Relations
• Dr. J. Keith Joung M.D., Ph.D.,
  Co-Founder & Scientific Advisory Board Member
• Dr. George McDonald Church Ph.D.,
  Co-Founder & Scientific Advisory Board Member
• Charlene Stern,
  Sr. VP & Chief Legal Officer
• Dr. Mark S. Shearman,
  Exec. VP & Chief Scientific Officer
• Harry R. Gill III,
  Sr. VP of Operations
• Dr. David R. Liu,
  Co-Founder & Scientific Advisory Board Member
• Dr. J. Keith Joung,
  Co-Founder & Scientific Advisory Board Member
• Dr. George M. Church,
  Co-Founder & Scientific Advisory Board Member
• Dr. Feng Zhang,
  Co-Founder & Scientific Advisory Board Member
• Douglas G. Cole,
  Director
• Katrine Bosley,
  President and CEO
• Kevin P Starr,
  10% owner
• Alexis Borisy,
  Director
• Alexandra Glucksmann,
  Chief Operating Officer
• Venture Management Co. Vi, ...,
  
• Ventures Fund Iv, L.P.Flags...,
  
• Kevin Bitterman,
  Director
• Gerald Frank Cox,
  Chief Medical Officer
• Ventures Fund Iv, L.P.Flags...,
  
• John Mendlein,
  Director
• Boris Nikolic,
  Director
• Andrew A. F. Hack,
  Chief Financial Officer
• Rock Ventures Iii, L.P.Thir...,
  
• Llc Bng0,,
  10% owner
• Bernadette Connaughton,
  Director
• Elliott M. Levy,
  Director
• Vickesh Myer,
  Chief Technology Officer
• Global Investors Lp Viking ...,
  
• Global Performance Llc Viki...,
  
• James E Deerfield Mgmt Iii,...,
  
• Baisong Mei,
  EVP, CHIEF MEDICAL OFFICER
• Mark S Shearman,
  EVP, CHIEF SCIENTIFIC OFFICER
• Meeta Chatterjee,
  Director
• Bruce Eaton,
  EVP, CBO AND CTO
• Emma Reeve,
  Director
• Erick Lucera,
  EVP, CHIEF FINANCIAL OFFICER
• Gilmore Neil O'neill,
  CEO
• Linda Burkly,
  EVP, CHIEF SCIENTIFIC OFFICER